HEATHER PRESTON

Heather Preston, M.D., stands as a distinguished Managing Partner at Pivotal BioVentures, a prominent venture capital firm dedicated to fostering innovation in the life sciences. In her pivotal role, Dr. Preston is instrumental in identifying and nurturing early-stage and growth-stage biotechnology companies that are developing transformative therapies. Her leadership at Pivotal BioVentures underscores the firm's commitment to investing in cutting-edge science with the potential to address significant unmet medical needs.

Dr. Preston's investment focus areas are sharply defined and strategically important. She primarily targets novel therapeutics, with a particular emphasis on companies operating within oncology, immunology, and rare diseases. Her keen eye for scientific merit and clinical potential allows her to pinpoint firms that are poised to make substantial impacts on patient outcomes. This specialized focus is informed by her profound understanding of biological mechanisms and disease pathways, ensuring that her investment decisions are grounded in robust scientific principles.

Before her tenure at Pivotal BioVentures, Dr. Preston built an impressive career trajectory that seamlessly blends clinical medicine with venture capital expertise. She began her professional journey as a physician, completing her residency in internal medicine at the prestigious Massachusetts General Hospital. Further specializing, she pursued a fellowship in hematology and oncology at the Dana-Farber Cancer Institute. This foundational medical experience provides her with invaluable insights into the complexities of drug development and the real-world needs of patients.

Transitioning into the investment world, Dr. Preston held significant roles at other leading venture capital firms. She served as a Managing Director at TPG Biotech, where she was responsible for leading investments in biotechnology companies. Prior to TPG, she was a Partner at New Enterprise Associates (NEA), one of the largest and most active venture capital firms, where she focused on healthcare investments. These experiences honed her skills in deal sourcing, due diligence, and portfolio management across a diverse range of biotech ventures.

Throughout her career, Dr. Preston has been associated with numerous successful investments that have brought innovative treatments to market. While specific public disclosures vary, her portfolio has included companies like Ambrx, Aravive, Five Prime Therapeutics, Forty Seven, NGM Biopharmaceuticals, and Principia Biopharma, among others, many of which have achieved significant clinical milestones or successful exits. Her ability to identify promising therapeutic platforms and support their growth from early development to commercialization highlights her strategic vision and impact in the biotech investment landscape. Heather Preston's unique blend of medical background and extensive venture capital experience positions her as a formidable force in driving the next generation of biomedical breakthroughs.